primary axillary hyperhidrosis
Dermatology · 2025–2025
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| glycopyrronium Treatment of severe primary axillary hyperhidrosis (PAHH) in patients aged 18 years or older, or as an alternative in patients who have failed or are… | Nov 2025 | Recommended with restriction | input received |
What the PBS pays
$57M in government benefit over 2024–25, across 795,332 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| glycopyrronium | $57.2M |
Appraised elsewhere
NICE, in England and Wales, has appraised 1 technology for this condition, recommending 1 . A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| glycopyrronium bromide creamGlycopyrronium bromide cream for treating severe primary axillary hyperhidrosis | TA1175 | recommended | 2026-07 |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.